Methotrexate treatment in dermatomyositis

Area of Science:

• Rheumatology
• Neurology
• Immunology

Background:

• Dermatomyositis is an idiopathic inflammatory myopathy.
• Corticosteroids are the first-line treatment but can be unpredictable and cause side effects.
• Severe cases may be refractory to standard therapies.

Purpose of the Study:

• To evaluate the efficacy of intravenous methotrexate in patients with severe, corticosteroid-refractory dermatomyositis.
• To assess the long-term outcomes of methotrexate treatment in this patient population.

Main Methods:

• Two patients with severe dermatomyositis unresponsive to corticosteroids received intravenous methotrexate.
• Treatment response was monitored over a 2-year follow-up period.
• Muscle enzyme levels were assessed to evaluate disease activity.

Main Results:

• Both patients showed satisfactory and sustained improvement with methotrexate therapy.
• Muscle enzyme studies indicated resolution of active muscle inflammation.
• One patient was bedridden and paralyzed, suggesting efficacy even in advanced disease stages.

Conclusions:

• Intravenous methotrexate can be an effective treatment option for severe dermatomyositis refractory to corticosteroids.
• Combination therapy with corticosteroids and methotrexate may be considered for initial treatment in severe dermatomyositis cases.
• Methotrexate offers a potentially safer and more predictable alternative or adjunct to long-term steroid therapy.